MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer

Molecular diagnostic tests (DNA, RNA, or protein based predictive classifiers) are covered for early-stage non-squamous NSCLC when the patient has AJCC 8th edition stage I or IIa disease, is sufficiently fit to tolerate chemotherapy, and adjuvant platinum-based chemotherapy is being considered. The test must be ordered by the treating physician (typically a medical oncologist, surgeon, or radiation oncologist) to inform the adjuvant chemotherapy decision; coverage applies only when all listed criteria are satisfied.

"Patient has histologically non-squamous non-small cell lung cancer (NSCLC) at American Joint Committee on Cancer (AJCC) 8th edition stage I or stage IIa."

Sign up to see full coverage criteria, indications, and limitations.